DOI QR코드

DOI QR Code

Detection of Recurrence in a Surveillance Program for Epithelial Ovarian Cancer

  • Suprasert, Prapaporn (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University) ;
  • Chalapati, Wadwilai (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University)
  • Published : 2013.12.31

Abstract

Ovarian cancer patients need a surveillance program for the detection of tumor progression after completion of treatment. The methods generally consist of history taking, physical examination, tumor marker monitoring and imaging. However, the details of recurrence detection with each method are not well defined. To clarify this issue, ovarian cancer patients who achieved complete or partial responses and developed tumor progression at the follow up time between January 2004 and December 2010 in University Hospital Chiang Mai, Thailand, were reviewed. Clinical data, CA 125 level and imaging results at the tumor progression time were recorded and analyzed. There were 144 ovarian cancer patients meeting the inclusion criteria with the mean age of 51 years and 62.5% of them were in an advanced stage. Complete response was achieved in 89 patients (61.8%) after primary treatment. The median progression free survival and overall survival were 15.5 months and 37.5 months, respectively. Abnormal symptoms presented in 49.3% of the studied patients and 59.7% developed physical examination abnormalities. In addition, CA 125 was elevated in 89.6% while in 74.3% of tumor progression was identified by CT-scan. Short treatment time period and a high level of CA 125 were significant independent prognostic factors in these patients. In conclusion, careful history taking, physical examination and monitoring of CA 125 levels are important methods for tumor progression detection in a surveillance program for epithelial ovarian cancer patients.

References

  1. Aebi S, Castiglione M (2008). Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19, 14-6.
  2. Chan KK, Tam KF, Tse KY, Ngan HY (2008). The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol, 110, 158-61. https://doi.org/10.1016/j.ygyno.2008.04.030
  3. Foley OW, Rauh-Hain JA, del Carmen MG (2013). Recurrent epithelial ovarian cancer: an update on treatment. Oncology, 27, 288-94.
  4. Fehm T, Heller F, Kramer S, et al (2005). Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res, 25, 1551-4.
  5. Geurts SM, van Altena AM, de Vegt F, et al (2011). No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study. Int J Gynecol Cancer, 21, 647-53. https://doi.org/10.1097/IGC.0b013e318212b87d
  6. Geurts SM, de Vegt F, van Altena AM, et al (2011). Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer, 21, 837-45. https://doi.org/10.1097/IGC.0b013e31821bb88c
  7. Levy T, Weiser R, Boaz M, et al (2013). The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol, 129, 165-8. https://doi.org/10.1016/j.ygyno.2012.12.024
  8. Menczer J, Chetrit A, Sadetzki S, et al (2006). Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. Gynecol Oncol, 103, 137-40. https://doi.org/10.1016/j.ygyno.2006.02.005
  9. Miller RE, Rustin GJ (2010). How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol ,22,498-502. https://doi.org/10.1097/CCO.0b013e32833ae8b6
  10. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2011. Available from: www.nccn.com
  11. Rustin GJ, van der Burg ME, Griffin CL, et al (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet, 376, 1155-63. https://doi.org/10.1016/S0140-6736(10)61268-8
  12. Salani R, Backes FJ, Fung MF, et al (2011). Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol, 204, 466-78. https://doi.org/10.1016/j.ajog.2011.03.008
  13. Tirkes T, Hollar MA, Tann M, et al (2013). Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics, 33, 1323-41. https://doi.org/10.1148/rg.335125214

Cited by

  1. Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6165
  2. Survival Outcomes of Recurrent Epithelial Ovarian Cancer: Experience from a Thailand Northern Tertiary Care Center vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10837
  3. Outcome of the Gynecologic Oncology Patients Surveillance Network Program vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4901